Similar articles

• Re: Hendrik Isbarn, Jehonathan H. Pinthus, Leonard S. Marks, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009;56:48-56.

  Friedman AE. Friedman AE. Eur Urol. 2009 Nov;56(5):e23; author reply e24. doi: 10.1016/j.eururo.2009.06.033. Epub 2009 Jul 3. Eur Urol. 2009. PMID: 19586711 No abstract available.
• Re: Michael J. Morris, Daisy Huang, William K. Kelly, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate. Eur Urol 2009;56:237-44.

  Drewa T, Chlosta P. Drewa T, et al. Eur Urol. 2010 Feb;57(2):e18-9; author reply e20. doi: 10.1016/j.eururo.2009.10.021. Epub 2009 Oct 20. Eur Urol. 2010. PMID: 19853990 No abstract available.
• Editorial comment on: A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.

  van der Poel HG. van der Poel HG. Eur Urol. 2009 Jul;56(1):103-4. doi: 10.1016/j.eururo.2009.02.023. Epub 2009 Feb 27. Eur Urol. 2009. PMID: 19282103 No abstract available.
• [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].

  Matveev BP, Bukharkin BV. Matveev BP, et al. Vopr Onkol. 1998;44(5):537-40. Vopr Onkol. 1998. PMID: 9884710 Review. Russian.
• New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

  Sharifi N. Sharifi N. Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Expert Opin Investig Drugs. 2010. PMID: 20524793 Review.